INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA):IJPS00]]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Clinical Trial Design In Drug : Enhance Safety And Efficacy

Sourabh Patil[1]*, Shreyash Koli[2], Suvarna Deshmukh[3], Tejas Kapase[4], Sachin Navale[5], Nilesh Chougule[6]

[1-4]*Students Ashokrao Mane institute of Pharmacy, Ambap.*
[5-6]*Assistant Professor Ashokrao Mane Institute of Pharmacy, Ambap*

ARTICLE INFO

Received: 23 Dec 2023
Accepted: 27 Dec 2023
Published: 16 Jan 2024

Keywords:
Clinical trials, Rigorous Protocol, Randomisation, Blinding, Adaptive design, Interim data Analysis.

DOI:
10.5281/zenodo.10517914

ABSTRACT

Clinical trials evaluate possible treatments on human participants, or subjects, in order to determine whether or not they should be licensed for broader usage in the general public. For a variety of reasons, clinical trials in India have historically been conducted worldwide. This study addresses clinical trials, namely those conducted in India. This are classified into different types based on their objectives, such as treatment trials, prevention trials, diagnostic trials, and others. Each type aims to address specific research questions related to the intervention's effectiveness. Clinical trials typically progress through several phases (Phase I to Phase IV) to evaluate different aspects like safety, dosage, efficacy, and potential side effects of the intervention. Each phase serves a specific purpose in the research process. Efficiency in clinical trials refers to conducting trials in a cost-effective and timely manner. Effectiveness assesses how well an intervention works in real-world conditions compared to its efficacy in controlled settings. Blinding involves concealing certain information from participants, researchers, or both, to minimize bias. Randomization ensures that participants are allocated randomly to different treatment groups, enhancing the validity and reliability of trial results.

INTRODUCTION

A clinical trial is a process designed to determine the efficacy and safety of a particular drug or device on humans [1,2]. New medications that fall into four phases are also included in clinical trials. For the approval of drugs, each phase is handled as a separate clinical trial. Generally, there are five phases in clinical trials:0, I, II, III, and IV [3,4].

A clinical study is divided into four phases: exploratory (phases 0 and 2), non-therapeutic (phase 1), therapeutic confirmatory (phase 3), and post-approval/post-marketing surveillance (phase 4). In order to gather information regarding the pharmacokinetics (dose tolerance) of the medicine before it is administered as part of the phase 1 trial among healthy individuals, phase 0, sometimes

***Corresponding Author:** Sourabh Patil
Address: *Students Ashokrao Mane institute of Pharmacy, Ambap.*
Email : sourabhpatil4793@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

referred to as the micro-dosing phase, is presently carried out on human volunteers after being done on animals in the past. Clinical research design can be broadly classified into two types of studies: observational/ non-interventional and interventional/experimental. A comparator group may be included in analytical research, such as case-control and cohort studies, or the studies may be descriptive only. Two categories of experimental research exist: randomised and non-randomized. There are various forms of designs for clinical trials, such as factorial, adaptive, superiority, non-inferiority, randomised withdrawal, parallel, crossover, and factorial designs [5]. Randomization reduces the possibility of selection bias influencing the results, it is essential for improving the quality of evidence-based research. Randomization typically involves random code generation programming, security-related random allocation concealment, and a separate random code manager. The generated randomization is then applied to the study after that [6]. It could be necessary to alter the clinical trial designs in order to guarantee the preservation of the study's validity. During a clinical trial, adaptive designs enable researchers to make necessary modifications without sacrificing the precision and dependability of the results. Additionally, it permits flexibility in trial conduct and data collection. Clinical researchers have not all agreed upon adaptive designs, despite these benefits. The lack of experience in the research community with these kinds of designs could be the reason for this. Adaptive designs have been applied to a range of clinical situations and phases of clinical research [7,8]. An alternative to conventional RCT design has been developed: adaptive designs. Conventional randomised controlled trials (RCTs) typically assign patients to intervention and control groups using a fixed randomization scheme that is used throughout the trial. Adaptive trials involve the observation and analysis of patient outcomes at predetermined intervals, which allow for the implementation of predetermined study design modifications based on these observations. Adaptive designs are described as "modern" and "novel" methods in the legislation [9].

Clinical Trial :

The systematic process of conducting a clinical trial aims to ascertain whether a drug or piece of medical equipment is safe and useful for curing, preventing, or identifying a disease or other medical term [10,11]. Any biological or behavioural research study with potential human subjects is called a clinical trial. What the study aims to do is provide answers regarding specific interventions, including new drugs, vaccinations, nutritional supplements, and medical technologies, among other things. Randomised control trials are the most prevalent kind of clinical trials (RCT) [12]. Phase 0: investigations on microdosing, a clinical study can have one or more phases, such as phases 1, 2, 3, and 4 [13].

Phases of Clinical Trials:

Phase l studies :

As this stage evaluates a medication's or device's safety. The testing process is currently in its early stages and could take several months to finish. Usually, between 20 and 100 healthy individuals participate in this phase. The goal of a phase 1 study is to ascertain the drug's or device's effects on humans, including its absorption, metabolism, and excretion (ADME). This stage also looks into side effects related to dosage. Approximately 70% of investigational drugs successfully complete this evaluation stage.

Phase II studies:

These assess the effectiveness of a medication or device. This is the follow-up testing phase. It involves hundreds of patients and takes many months to two years to finish. Phase II studies are primarily randomized trials wherein one group of patients receives the experimental drug and the

other group, referred to as the "control" group, receives either a standard treatment or a placebo. Many of these studies are "blinded," which means that neither the researchers nor the patients are aware of who was given the experimental medication. Roughly one-third of experimental medications successfully complete their Phase I and Phase II trials.

Phase III studies:

Trials with blinding and randomization involving hundreds to thousands of participants are assessed at this level. This is a lengthy testing process that can take several years to finish. It gives the researchers and the regulatory body a more complete grasp of the advantages, potential side effects, and efficacy of the medication or device. Between 70 and 90 percent of medications that start Phase III trials are successfully tested through this stage.

Phase IV studies:

The term "post-marketing surveillance trials" is another name for this stage. They take place following a medication or device's approval from a regulatory body to be sold to consumers. Pharmacies now aim to do three things: (1) compare a medication with other medications already on the market; (2) monitor a medication's long-term efficacy and impact on a patient's quality of life; and (3) determine the cost-effectiveness of a medication therapy in relation to other novel and current therapies. Based on the findings of phase IV trials, a drug or device may be taken off the market or have its usage limited [14,15,16].



Fig 1: Phases of Clinical Trials

Clinical trial design Overview :

Clinical trials are primarily designed to monitor the outcomes of human subjects in "experimental" settings that are managed by the researcher. On the other hand, in non-interventional study designs (such cohort and case-control studies), the researcher measures the exposure of interest without making any changes to it. Clinical trials are usually favoured because they enable randomization of the intervention, hence eliminating selection bias resulting from the imbalance of unknown/immeasurable confounders. The ability to identify causality in an RCT is one of its innate strengths. However, randomized clinical trials are still susceptible to a number of limitations, including contamination, Misclassification or information bias in the exposure or outcome, as well as co-interventions (in which a higher frequency of additional intervention is given to one arm than the other).A rigorous clinical trial must be executed successfully, and this requires selecting the

appropriate study population. Even though every participant gave their free consent for the intervention, there's a chance that the cohort that was enrolled isn't exactly like the population as a whole. Known as "volunteer bias," this kind of selection bias can result from a variety of factors like the prerequisites for study eligibility, intrinsic subject characteristics (like the subject's socioeconomic status, health, attitude, and belief systems, and geographic distance from the study site), or the investigator's subjective exclusion based on low enrolment compliance or overall prognosis [17]. While recruiting a relatively homogeneous population based on predefined characteristics is one way that randomized controlled trials (RCTs) attempt to achieve internal validity; narrow inclusion and exclusion criteria may limit the external validity (also referred to as "generalizability") of the study to a larger population of patients with highly prevalent comorbidities who may not be included in the sample cohort. This subject focuses on the reasons that an experimental treatment's "efficacy," or how well it performs in a lab setting, may differ from its "effectiveness," or how valuable it is when used in the "real world." Attempts to improve generalizability and patient recruitment by offering free medical care and financial incentives [18].

Clinical Trials in India:

It's believed that doing international clinical trials will be beneficial in India. India is thought to be the site of almost 20% of all clinical trials carried out worldwide. India, the world's second-most populous nation, can make a substantial contribution to international drug development initiatives. When compared to other developed nations, India has many benefits: a sizable patient base, highly educated workforce, a broad spectrum of diseases, reduced operating and drug costs, a favourable economic climate, and—above all—the ease with which clinical sites can be established because English is the primary language in the nation. India's equivalent of the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) is the Office of the Drugs Controller General (India) (DCGI). The federal representative in charge of all matters pertaining to pharmaceuticals in India is the DCGI. The FDA commissioner is akin to the DCGI. For drug trials, India abides with IND regulations 21CFR:312, which are the same as Schedule Y. DCGI does not have separate offices and centres in India to manage different product categories on its own. However, the DCGI personally signs each application that is submitted to his office. Not just applications for clinical trials are covered here; these also involve manufacturing, importing and exporting regulated items, and marketing approval for pharmaceuticals and medical devices. India conducts clinical trials in accordance with ICH E6 guidance [19,20,21].

Fig 2: Clinical trial in India

Efficacy and effectiveness :

Efficacious versus effective nutrition is a key distinction in RCTs on human nutrition. The outcome of an intervention under optimal circumstances is referred to as efficacious. In order to conduct efficacy studies, all foods, beverages,

and/or a nutritional formulation must be provided to participants either in an inpatient setting (such as a metabolic ward, hospital) or in a free-living setting (such as a test kitchen or metabolic research unit). In an inpatient setting, participants are closely observed; in a free-living setting, on the other hand, they may eat up to one meal per day under supervision and the remainder on their own. The scope and diversity of participant characteristics in an efficacy study are typically constrained by time, logistics, and available resources. The Thrombogenic Activity Trial and Dietary Effects on Lipoproteins are two examples of efficacy studies [22,23]. An efficacy trial would be carried out if an efficacy study produced results that were clinically meaningful. An efficacy study, also known as a pragmatic trial, attempts to replicate an intervention's implementation in less controlled conditions in a "real world" scenario. It typically has a lower participant load and more participants. In this scenario, study participants are given instructions by researchers via Web-based meetings, individual or group settings, on how to adjust their diet (e.g., buy, prepare, and/or substitute specified foods and beverages). This instruction may or may not include the provision of special study items. Two examples of successful research are the PREMIER trial and the Women's Health Initiative Intervention trial [24,25].

	Efficacy studies	Effectiveness studies
Aim	To evaluate models/protocols in order to establish whether or not the expected outcome can be observed under ideal circumstances	To evaluate models/protocols as practised in everyday clinical settings; to identify moderating factors that may influence outcome
Participants	Strict inclusion/exclusion criteria (probably results in a homogeneous population)	Limited exclusion criteria (probably results in a more heterogeneous population)
Intervention	Standardised and strictly adherent to protocols; delivered by highly trained and experienced clinicians	Some flexibility to account for needs of participants and service context; delivered by clinicians who may have a range of training and experience
Validity	High internal validity	High external validity (while maintaining adequate internal validity)
Question	Does the intervention work?	Does the intervention benefit patients?

Fig 3 : Difference Between Efficacy and Effectiveness

Rigorous Protocol :

What Is a Protocol?

Clinical research is carried out in accordance with a concept (a protocol) or a strategy. The guidelines for carrying out the trial are laid out in the protocol. It explains each crucial component of the study and how it will be carried out, providing an illustration of what will be made. It also covers the study's duration, the participants' eligibility, the drugs used, and consequently, the associated testing. A principal researcher oversees a protocol. The study's effectiveness and safety will be guaranteed by the research team members who will routinely evaluate the participants' health.

Why the Clinical Trial Protocol are Needed ?

In general, a protocol describing the reasoning behind the approach selected, security measures for research participants, recommended statistical analysis, and specifics regarding organizational, administrative, and research funder information

from the trial's inception to its conclusion must be included in all randomised clinical trials. Consequently, clear, concise, and well-written protocols continue to be essential to conducting clinical trials because they allow for prompt and thorough trial evaluation [26,27].

Main Protocol /Master Protocol :

A main protocol, formerly known as a master protocol, addresses the notion that molecular heterogeneity of cancer underlying otherwise uniform-appearing histology and is ultimately accountable for clinical outcomes (ie, responses to medicines and/or survival). Generally speaking, a main protocol is an organized clinical trial framework with the ability to evaluate several regimens at once and a molecular screening process; it is typically based on the molecular characterization of particular cohorts. After a screening procedure identifies participants with biomarkers or other characteristics of interest, these individuals are allocated to arms within a trial or to different trials. This strategy improves screen success rate, efficacy of drug development, and maybe individual therapeutic benefit. This strategy is distinctive in that it combines the interests of basic scientists, physicians, and patients in a way that fosters intimate cooperation for the advancement of biology and enhancement of patient care. Acknowledging the connection between cancer biology, precision medicine, and clinical result helps achieve this. Next, we shall discuss popular main protocol designs, such as the basket, umbrella, and platform trials [28].

Randomization :

An established technique used in research to prevent subject selection bias that could affect the outcome of the intervention or experiment under study is randomization. Ensuring scientific validity is a fundamental principle of experimental study designs. It offers a means of preventing subject selection bias in the final results by preventing the prediction of which subjects are assigned to which group. Since most baseline characteristics of the groups were similar before randomization, this also ensures comparability between them and aids in the impartial interpretation of the results pertaining to the intervention/experiment group. Randomization can be achieved in a number of ways, from using statistical techniques and computer software to something as basic as a "flip of a coin." Randomization can be further explained by using three different types of randomizations: stratified randomization, block randomization, and basic randomization.

1. Simple Randomization :

In simple randomization, a constant probability is used to randomly assign subjects to experiment/intervention groups. That is, there is a 0.5 chance that the subject will be assigned to either of the two groups, A and B. There are several methods to accomplish this, the simplest being a "flip of a coin" or the utilization of random tables or integers. One advantage of this process is that it does not introduce bias in selection. The methodology's shortcoming, however, is the disparity in the number allotted to each group and the prognostic factors between groups. As a result, it is more challenging in studies with lower sample sizes.

2. Block Randomization :

Block randomization creates groupings of participants according to characteristics they have in common. The goal of block randomization is to keep the number of subjects assigned to each experiment/intervention group equal. Consider the following scenario: there are four participants in each block, and two of those subjects are randomly assigned to each group. Consequently, two subjects will be in one group and two subjects in another [29]. This methodology's disadvantage is that subject selection still requires some degree of predictability because prognostic factor randomization is not used.

3. Stratified Randomization :

Using stratified randomization, participants are defined based on particular factors, or strata [30]. As covariates, prognostic factors can be considered age, for example. Next, a particular population within each age category can be assigned at random to an experiment or intervention group. One advantage of this methodology is that it makes it possible to compare the experiment and intervention groups, which enhances the effectiveness of result analysis. Nevertheless, prior to randomization, the covariates need to be determined and assessed when employing this methodology. The sample size will influence the number of strata that would need to be chosen for a study.

Blinding :

The method of blinding is employed in study designs to consciously conceal information about group assignment from subject participants, researchers, and/or data analysers [31]. The aim of blinding is to reduce the impact of knowing oneself to be a member of a specific group on the outcome of the research. There are three methods for blinding: single blinding, double blinding, or triple blinding [32]. During a single-blind study, neither the healthy volunteer nor the patient is aware of whether they are getting the test intervention or a placebo. In a double-blind trial, neither the patient nor the subject nor the experimenter knows who is in the test group and who is in the control group; only the observer is aware of this information. In a triple-blind RCT, the identity or nature of the treatment that was given is unknown to any of the three trial participants. Because of this, the triple-blind RCT allows for the results to be independent of biases of any type and is entirely free of them. In double- and triple-blind tests, the keys that identify the patients or human subjects and the group to which they belonged are maintained by a different party and are only handed to the researcher at the end of the study [33].

Limitation of blinding:

Blinding has some inherent limitations, despite the fact that it is generally accepted as a very effective technique for eliminating bias. It is therefore important for researchers and clinicians to be aware of these limitations. Blinding often takes a lot of time and money [34]. Additionally, it has been proposed that blinding may have a negative effect on treatment after a clinical trial is over [35].

Adaptive Design Clinical Trials :

The ability to adapt trial design and/or statistical techniques after the trial has started without jeopardizing the trial's validity and integrity is what defines adaptive clinical trial design. Clinical trials can be conducted more quickly, adaptably, and effectively when they employ adaptive design. Because of the degree of flexibility required, these trial designs are sometimes referred to as flexible designs. Essentially, a clinical trial that has been adaptively constructed anticipates and accommodates major modifications along the way, saving the need for a completely new study or protocol revision. Adaptive design has the potential to be very exciting in the context of clinical trials in global health, both for product development and for disease management trials where the approach may be applied successfully. The usual phase I, II, and III approaches are used in disease management trials, but this is laborious and frequently nonsensical because these phases were created to support new drug and vaccine registration trials. A more practical and logical approach is required in disease management trials, and adaptive design may be effective. While adaptive design is becoming more and more popular, little thought has been given to the potential benefits this method could have for research in underdeveloped nations [36]. Flexibility in this context does not mean that trial conditions can be altered at any point. Prior

planning and information from the study itself should serve as the basis for the revisions and adjustments. As a result, an adaptive design clinical trial is defined as "a study that includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from study subjects" in the FDA's recently released draft guidance for the industry on adaptive design clinical trials [37].

Types Of Adaptive Design Clinical Trial :

Clinical trials often use a range of adaptive design strategies, including as group sequential, drop-the-loser, adaptive dose discovery, biomarker-adaptive, adaptive treatment-switching, adaptive randomization, and hypothesis-adaptive designs. What sets these strategies apart are the modifications they make.

A. Adaptive Randomization Design :

Modifying the randomization schedule in response to varying or uneven treatment assignment probability is possible with adaptive randomization. The objective is to increase the likelihood of success. Using the suggested alteration will extend the experiment beyond what was anticipated because it depends on the response of the patients who have already enrolled in the trial.

B. Group Sequential Design :

If there are safety or efficacy issues, a trial may be stopped early when employing group sequential design. The results of the interim analysis may also lead to additional modifications. Group sequential designs are already used in the clinical cancer setup. The most well-known example is the "3+3" Phase I trial design, which is used to find the maximum tolerated dose. In a 3+3 experiment, the initial dose is administered to three patients, and if no dose-limiting adverse effects are seen, three more individuals are added at a higher dose. If limiting toxicity occurs in the first group even once, three more patients are added at the same dose.

C. Sample Size re- Estimation Design :

This type of design allows for sample size adjustments or recalculations in response to interim observed data. Reproducibility probability, conditional power, and/or treatment effect-size characteristics will determine whether this is done blindingly or unblinkingly. It's not a smart idea to start with a small number of individuals and then re estimate the sample size at the intermediate analysis since you could miss the clinically significant difference that the ongoing research is looking for [38,39].

D. Drop-The-Loser-Design :

Subjects who were discovered to have had inadequate care at the interim analysis may be removed thanks to this design. Currently, additional treatment arms might be added based on the interim analysis's findings.

E. Adaptive-Dose Finding Design :

In early-phase clinical development, adaptive dose-finding designs are commonly used to determine the lowest effective dose and the highest acceptable dose, which are used to set the dose level for the future phase of clinical trials [40].

F. Biomarker-Adaptive Design :

With this type of design, the ongoing experiment can be modified in accordance with to how different biomarkers linked to the disease under investigation respond. The appropriate patient population can be chosen, the natural course of a disease can be identified, early disease detection can be facilitated, and personalised medicine can be developed with the aid of a biomarker-adaptive design [41,42]. It's critical to keep in mind that discovering biomarkers associated with clinical outcomes is not the same as developing a model in clinical development that forecasts clinical outcomes based on pertinent biomarkers [43].

G. Adaptive Treatment-Switching Design :

In a treatment-switching strategy, it is acceptable to move a patient from one therapy choice to another if safety or effectiveness issues occur. However, if the disease under consideration has a poor prognosis, estimating the survival rate in these kinds of trials will become very challenging. As the disease progresses, a significant proportion of subjects may switch treatments, which can be confusing [44].

H. Hypothesis-Adaptive Design :

An adaptive-hypotheses design is one that allows for changes or revisions to hypotheses in response to interim analysis results. Adaptive hypothesis design is often finished before data unblinding or database lock. Changing the focus between the primary and secondary study endpoints, and going from a superiority hypothesis to a non-inferiority hypothesis, are two examples [45].

Interim Data Analysis :

In clinical trials, the term "interim analysis" can refer to several different things. Generally speaking, interim analyses aid in directing choices regarding general clinical trial adjustments, particularly those concerning the study sample size or recruitment goals [46,47]. Interim analysis is a reliable, rational way to approach clinical trials that considers lessons acquired during a clinical study and after it is finished without compromising its validity or integrity. This approach might take into account modifications to all program-related assets and operations, such as adjustments to recruiting, monitoring, and logistical protocols. Realistically speaking, the study needs to be able to measure the desired outcomes continuously as well as provide timely data and summaries of those measurements to various audiences based on the role of the study. This involves regularly monitoring trial data collected on case report forms and developing performance measures that enable operational changes in a clinical context. The soaring expense of clinical research combined with the numerous trial failures that have happened—many of which were costly and publicly publicized failures of important late-stage trials—have raised interest in this approach.

Such an interim analysis's most straightforward outcome is an early conclusion about the study's futility or continuation. By taking a logical approach, clinical researchers can also apply the same fundamental management techniques as most contemporary businesses, making decisions based on real-time data and analysis that continuously optimise operation

Interim analysis and stopping rule :

A variety of group sequence designs that support the study's blinding and a predefined overall type I error rate while allowing a limited number of planned analyses logically and practically justify the use of this strategy in clinical trials. Interim analyses should ideally be handled by a separate organisation from the one in charge of the clinical trial's day-to-day operations. A clinical trial can be positive stopped early using a variety of prospective statistical techniques [48,49]. The more stringent stopping conditions for interim analyses based on limited data do not apply to earlier studies, which may have stopping P-values that are relatively near to the nominal thresholds of significance. Because there are no standardized statistical approaches for these operations, they provide significant challenges during the evaluation process. By definition, an adaptive design is a study that incorporates a prospectively planned opportunity to modify one or more specified aspects of the study design and hypotheses based on the analysis of data (usually interim data) from study participants. This definition is similar to the one provided by the Adaptive Design Scientific Working Group. As a result, revisions should adhere to established principles, as agreed upon by the FDA and the Adaptive Design Scientific Working Group. But the FDA defines this in a broader sense: "The word prospective here refers to the fact that the

adaptation was planned prior to any staff members involved in revision planning examining data in an unblinded manner. If the participants' blind status is clearly maintained at the time the modification plan is suggested, this can include plans that are added to or made final after the study has begun [50].

Planned And Unplanned Interim Analysis :

The fact that such interim analyses were conducted using data not directly related to clinical trial operations should not be used to justify the nominal P-values; rather, the results of these planned or unplanned interim analyses must be adjusted. These are the most frequent interim analysis problems that statistical reviewers encounter during the review process, and they are also possibly the hardest to resolve. When faced with unplanned interim analyses during the clinical trial review process, several statistical reviewers have turned to this ad hoc approach. In addition to this ad hoc method, when the precise number of unplanned interim analyses that were actually conducted is known, the more adaptable alpha-spending function method has also been proposed as a candidate for retrospective adjustment of P values owing to unplanned interim analyses. The following is an illustration of multiple looks for a comparative trial where the efficacy of two treatments is being compared.

H0:p2 equals p1.

H1:p2 is greater than p1.

According to a standard design, we need roughly 100 patients per arm for 80% power with an alpha of 0.05. This is based on the assumption that p2 = 0.50 and p1 = 0.30, which yields a difference of 0.20. What therefore occurs if $P < 0.05$ is discovered prior to the enrolment of every patient? Why is it not possible for us to examine the data several times during the trial and determine that, if $P < 0.05$, one treatment is superior [51].

Diverse participants representation contributes to a comprehensive evaluation process :

In order to guarantee that the trial population is representative of the patients who will use the medication or medicinal product and that the results are generalizable, a diverse group of participants is required in clinical trials. A review of 167 novel molecular entities that the Food and Drug Administration (FDA) approved between 2008 and 2013 found that about 1 in 5 of them had variations in exposure, response, or both between racial or ethnic groups [52]. A flaw that still exists in trials today. As an example, according to data from 2011, the proportion of African Americans and Hispanics in the US population was 12% and 16%, respectively, but only 5% and 1% of trial participants identified as such [53]. The pharmaceutical industry, academic institutions, and clinical research in general continue to face challenges in expanding clinical trial diversity in an efficient, long-lasting, and scalable way. As a result, we worked together with the Association of Black Cardiologists, representatives from a sizable biopharmaceutical company that prioritises research, clinical trial specialists, and other important stakeholders to conduct a collaborative study aimed at identifying potential implementation and communication strategies for addressing the obstacles that minority participation in US clinical trials faces. We concentrated particularly on minority patients, trial coordinators, physicians who served minority populations as referrers, and investigators. Our overarching objective was to create potentially long-lasting solutions that would assist all relevant parties and result in the inclusion of diversity in clinical trials as a fundamental component of the clinical research paradigm [54].

Applications :

1. Treatment Efficacy and Safety Assessment
2. Clinical Guidelines and Best Practices
3. Healthcare Policy and Decision Making
4. Quality Improvement and Patient Outcomes
5. Comparative Effectiveness Research

6. Medical Education and Training
7. Health Technology Assessment
8. Public Health Interventions

CONCLUSION

Clinical evaluation methods are crucial for assessing the safety and efficacy of medical interventions. Rigorous trials, ranging from Phase I to Phase III, provide a systematic framework for drug performance assessment. Well-designed studies, including endpoints, blinding, and randomization, ensure reliability and validity of results. These evaluations guide regulatory decisions, shape clinical practice, and enhance patient care. A commitment to robust evaluation methods is essential for ensuring healthcare and pharmaceutical advancements' integrity. Clinical evaluation methods are crucial for assessing the safety and efficacy of medical interventions. They involve a stepwise progression through Phase I, II, and III studies, ensuring comprehensive scrutiny of drug performance. Rigorous trial designs, participant selection, and blinding contribute to reliability and validity. This systematic approach ensures regulatory standards are met, promoting evidence-based healthcare decision-making. Continuous improvement and innovation are vital for advancing medical knowledge and delivering safe treatments.

REFERENCES

1. Nayak C, Oberai P, Varanasi R, Baig H, Ch R, Reddy GR, et al. A prospective multi centric open clinical trial of homeopathy in diabetic distal symmetric polyneuropathy. Homeopathy 2013; 102:130-8.
2. Bykerk VP, Keystone EC, Kuriya B, Larché M, Thorne JC, Haraoui B. Achieving remission in clinical practice: lessons from clinical trial data. Clin Exp Rheumatol 2013; in press.
3. Brater DC and Walter JD. Clinical pharmacology in the Middle Ages: Principles that presage the 21st century. Clin Pharmacol Therap 2000; 67: 447-50.
4. http://clinicaltrials.gov/ct2/aboutstudies/glossary. Assessed on April 10,2013.
5. The current perspectives in clinical research: computer-assisted drug designing, ethics, and good clinical practice. Kandi V, Vundecode A, Godalwar TR, Dasari S, Vadakedath S, Godishala V. Borneo J Pharm. 2022;5:161–178.
6. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
7. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. Burnett T, Mozgunov P, Pallmann P, Villar SS, Wheeler GM, Jaki T. BMC Med. 2020;18:352.
8. Opportunity for efficiency in clinical development: an overview of adaptive clinical trial designs and innovative machine learning tools, with examples from the cardiovascular field. Sverdlov O, Ryeznik Y, Wong WK. Contemp Clin Trials. 2021;105:106397.
9. United States Government. Rules committee print 114-67, text of House amendment to the Senate, amendment to H.R. 34, Tsunami Warning, Education, and Research Act of 2015, 2016:162–3. 114th Congress.
10. Microbes, clinical trials, drug discovery, and vaccine development: the current perspectives. Kandi V, Suvvari TK, Vadakedath S, Godishala V. Borneo J Pharm. 2021;4:311–323.
11. Research question, objectives, and endpoints in clinical and oncological research: a comprehensive review. Purna Singh A, Shahapur PR, Vadakedath S, et al. Cureus. 2022;14:0.

12. Spieth PM, Kubasch AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T, et al. Randomized controlled trials - A matter of design. Neuropsychiatr Dis Treat. 2016;12:1341–9.
13. Clinical research: an overview of study types, designs, and their implications in the public health perspective. Kandi V, Vadakedath S. Am J Clin Med Res. 2021;9:36–42.
14. The Lancet (2009). "Phase 0 trials: A platform for drug development?". The Lancet. 374 (9685): 176–118.
15. Yang, Z. J., et al. (2010). "Motivation for Health Information Seeking and Processing About Clinical Trial Enrollment." Health Communication 25(5): 423-436.
16. Life Sciences Strategy Group, (May 2009) "Clinical Trial Technology Utilization, Purchasing Preferences & Growth Outlook" Syndicated Publication,
17. Gravetter FJ, Forzano LAB. Research Methods for the Behavioral Sciences. 3rd ed Wadsworth Cengage Learning; Belmont, CA: 2009.
18. Mapstone J, Elbourne D, Roberts I. Strategies to improve recruitment to research studies. Cochrane Database Syst Rev. 2007;(2) MR000013
19. "India: Prime Destination for Unethical Clinical Trials". Common Dreams.
20. Paul J, Seib R, Prescott T (Mar 2005). "The Internet and Clinical Trials:Background, Online Resources, Examples and Issues" (Free full text).Journal of medical Internet research. 7 (1): e5.
21. ICH Guideline for Good Clinical Practice: Consolidated Guidance
22. Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, Pearson T, Roheim P, Ramakrishnan R, Reed R Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA study, protocol 1 Arterioscler Thromb Vasc Biol, 18 (3) (1998), pp. 441-449.
23. Berglund L, Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Dennis BH, Roheim PS Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states.
24. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
25. Appel LJ., Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial.
26. Dwan K, Gamble C, Williamson PR, Kirkham JJ. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias — An Updated Review. Boutron I, editor. PLoS ONE [Internet]. Public Library of Science (PLoS); 2013 Jul 5;8(7):e66844
27. Lexchin J. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ [Internet]. BMJ; 2003 May 29;326(7400):1167–70.
28. Hyman DM, Solit DB, Arcila ME, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today. 2015; 20: 1422-1428.

29. Altman DG, Bland JM. How to randomise. BMJ. 1999; 319: 703-704.
30. Suresh K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. J Hum Reprod Sci. 2011; 4: 8-11.
31. Karanicolas PJ, Farrokhyar F, Bhandari M. Practical tips for surgical research: Blinding: Who, what, when, why, how? Can J Surg. 2010; 53: 345-348.
32. Lim HJ, Hoffmann RG. Study design: The basics. Methods Mol Biol. 2007; 404: 1-17.
33. Neutel JM and Smith DHG. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens. 2003; 5(1): 58-63.
34. Wan M., Orlu-Gul M., Legay H., Tuleu C. Blinding in pharmacological trials: The devil is in the details. Arch. Dis. Child. 2013;98:656–659. doi: 10.1136/archdischild-2013-304037.
35. Blader J.C. Can keeping clinical trial participants blind to their study treatment adversely affect subsequent care? Contemp. Clin. Trials. 2005;26:290–299. doi: 10.1016/j.cct.2005.01.003.
36. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, Gibbons RD. Adaptive designs for randomized trials in public health. Annu Rev Public Health. 2009;30:1–25.
37. Guidance for industry: Adaptive design clinical trials for drugs and biologics. Washington DC, USA: Food and Drug Administration; 2010. Food and Drug Administration.
38. Chow SC, Chang M. Adaptive design methods in clinical trials- a review. Orphanet J Rare Dis. 2008;3:11.
39. Lowe D. What you need to know about adaptive trials.
40. An adaptive dose-finding design is often used in early-phase clinical development to identify the minimum effective dose and the maximum tolerable dose, which is used to determine the dose level for the next phase clinical trials.
41. Charkravarty A. Regulatory aspects in using surrogate markers in clinical trials. In: Burzykowski T, Molenberghs G, Buyse M, editors. The Evaluation of Surrogate Endpoint. New York: Springer; 2005.
42. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat. 2007;6:227–44.
43. Chang M. New York: CRC Press; 2007. Adaptive Design Theory and Implementation Using SAS and R.
44. Chow SC, Chang M. Adaptive design methods in clinical trials- a review. Orphanet J Rare Dis. 2008;3:11.
45. Hommel G. Adaptive modifications of hypotheses after an interim analysis. Biom J. 2001;43:581–9.
46. Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. Switzerland: Springer; 2015.
47. Proschan MA, Lan KG, Wittes JT. Statistical Monitoring of Clinical Trials: A Unified Approach. New York, NY: Springer Science & Business Media; 2006.
48. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: A systematic review. JAMA. 2005;294:2203–9.
49. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218–28.
50. Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. 2010. [Last accessed on 2016 Jun 15.

51. Sinha BK. Interim Analysis in Clinical Trial, ppt. [Last accessed on 2016 Feb 21.
52. A. Ramamoorthy, M.A. Pacanowski, J. Bull, et al.Racial/ethnic differences in drug disposition and response: review of recently approved drugs.
53. The Society for Women's Health Research United States Food and Drug Administration Office of Women's Health. Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials; 2011.
54. V.T. Covello Effective risk and crisis communication during water security emergencies: summary report of EPA sponsored message mapping workshops: National Homeland Security Research Center, Office of Research and Development, US Environmental Protection Agency

HOW TO CITE: Sourabh Patil, Shreyash Koli, Suvarna Deshmukh, Tejas Kapase, Sachin Navale, Nilesh Chougule, Clinical trial design in drug : enhance safety and efficacy, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 1, 274-287. https://doi.org/10.5281/zenodo.10517914